Base de dados : MEDLINE
Pesquisa : D02.033.100.624.915 [Categoria DeCS]
Referências encontradas : 3469 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 347 ir para página                         

  1 / 3469 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29114841
[Au] Autor:Roy Chowdhury U; Rinkoski TA; Bahler CK; Millar JC; Bertrand JA; Holman BH; Sherwood JM; Overby DR; Stoltz KL; Dosa PI; Fautsch MP
[Ad] Endereço:Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States.
[Ti] Título:Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.
[So] Source:Invest Ophthalmol Vis Sci;58(13):5731-5742, 2017 Nov 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: Cromakalim prodrug 1 (CKLP1) is a water-soluble ATP-sensitive potassium channel opener that has shown ocular hypotensive properties in ex vivo and in vivo experimental models. To determine its mechanism of action, we assessed the effect of CKLP1 on aqueous humor dynamics and in combination therapy with existing ocular hypotensive agents. Methods: Outflow facility was assessed in C57BL/6 mice by ex vivo eye perfusions and by in vivo constant flow infusion following CKLP1 treatment. Human anterior segments with no trabecular meshwork were evaluated for effect on pressure following CKLP1 treatment. CKLP1 alone and in combination with latanoprost, timolol, and Rho kinase inhibitor Y27632 were evaluated for effect on intraocular pressure in C57BL/6 mice and Dutch-belted pigmented rabbits. Results: CKLP1 lowered episcleral venous pressure (control: 8.9 ± 0.1 mm Hg versus treated: 6.2 ± 0.1 mm Hg, P < 0.0001) but had no detectable effect on outflow facility, aqueous humor flow rate, or uveoscleral outflow. Treatment with CKLP1 in human anterior segments without the trabecular meshwork resulted in a 50% ± 9% decrease in pressure, suggesting an effect on the distal portion of the conventional outflow pathway. CKLP1 worked additively with latanoprost, timolol, and Y27632 to lower IOP, presumably owing to combined effects on different aspects of aqueous humor dynamics. Conclusions: CKLP1 lowered intraocular pressure by reducing episcleral venous pressure and lowering distal outflow resistance in the conventional outflow pathway. Owing to this unique mechanism of action, CKLP1 works in an additive manner to lower intraocular pressure with latanoprost, timolol, and Rho kinase inhibitor Y27632.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Humor Aquoso/fisiologia
Cromakalim/uso terapêutico
Pressão Intraocular/efeitos dos fármacos
Pró-Fármacos/uso terapêutico
[Mh] Termos MeSH secundário: Amidas/uso terapêutico
Animais
Segmento Anterior do Olho/efeitos dos fármacos
Sinergismo Farmacológico
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Meia-Idade
Soluções Oftálmicas
Prostaglandinas F Sintéticas/uso terapêutico
Piridinas/uso terapêutico
Coelhos
Esclera/irrigação sanguínea
Timolol/uso terapêutico
Tonometria Ocular
Pressão Venosa/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amides); 0 (Antihypertensive Agents); 0 (Ophthalmic Solutions); 0 (Prodrugs); 0 (Prostaglandins F, Synthetic); 0 (Pyridines); 0G4X367WA3 (Cromakalim); 138381-45-0 (Y 27632); 6Z5B6HVF6O (latanoprost); 817W3C6175 (Timolol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171109
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22538


  2 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28768500
[Au] Autor:Rolle T; Spinetta R; Nuzzi R
[Ad] Endereço:Eye Clinic, Department of Surgical Sciences, University of Torino, Via Juvarra 19, 10122, Torino, Italy. teresa.rolle@unito.it.
[Ti] Título:Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
[So] Source:BMC Ophthalmol;17(1):136, 2017 Aug 03.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The effects of preservatives of antiglaucoma medications on corneal surface and tear function have been widely shown in literature; it's not the same as regards the active compounds themselves. The purpose of our study was to compare Ocular Surface Disease (OSD) signs and symptoms of Tafluprost 0.0015% versus preservative free (PF) Timolol 0.1% eyedrops in ocular hypertensive (OH) and in primary open-angle glaucoma (POAG) patients. METHODS: A cross-sectional study included patients in monotherapy for at least 36 months with Tafluprost 0.0015% (27) or PF Timolol 0.1% (24) and 20 healthy age and sex-matched volunteers. All subjects underwent clinical tests (Schirmer I and break-up time), in vivo confocal microscopy (IVCM) and were surveyed using Ocular Surface Disease Index (OSDI) and Glaucoma Symptoms Scale (GSS) questionnaires. The groups were compared with ANOVA, Kruskal-Wallis test, t-test, Mann-Whitney test and Bonferroni's adjustment of p-values. RESULTS: No significant differences were found in questionnaires scores, clinical tests, IVCM variables between therapy groups. Tafluprost 0.0015% group showed significantly higher OSDI score, basal epithelial cells density, stromal reflectivity, sub-basal nerves tortuosity (p = 0.0000, 0.037, 0.006, 0.0000) and less GSS score, number of sub-basal nerves (p = 0.0000, 0.037) than controls but similar clinical tests results (p > 0.05). PF Timolol group had significantly higher OSDI score, basal epithelial cells density, stromal reflectivity and sub-basal nerve tortuosity (p = 0.000, 0.014, 0.008, 0.002), less GSS score, BUT and number of sub-basal nerves (p = 0.0000, 0.026, 0.003) than controls. CONCLUSIONS: Compared to PF Timolol 0.1%, Tafluprost 0.0015% showed similar safety with regards to tear function and corneal status and a similar tolerability profile. Both therapy groups show some alterations in corneal microstructure but no side effects on tear function except for an increased tear instability in PF Timolol 0.1% group. Ophtalmologists should be aware that even PF formulations may lead to a mild ocular surface impairment.
[Mh] Termos MeSH primário: Tolerância a Medicamentos
Glaucoma de Ângulo Aberto/tratamento farmacológico
Pressão Intraocular/efeitos dos fármacos
Hipertensão Ocular/tratamento farmacológico
Prostaglandinas F/administração & dosagem
Timolol/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Anti-Hipertensivos/administração & dosagem
Estudos Transversais
Relação Dose-Resposta a Droga
Feminino
Seguimentos
Glaucoma de Ângulo Aberto/fisiopatologia
Seres Humanos
Masculino
Microscopia Confocal
Meia-Idade
Hipertensão Ocular/fisiopatologia
Soluções Oftálmicas
Conservantes Farmacêuticos
Lágrimas/química
Fatores de Tempo
Tonometria Ocular
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Ophthalmic Solutions); 0 (Preservatives, Pharmaceutical); 0 (Prostaglandins F); 1O6WQ6T7G3 (tafluprost); 817W3C6175 (Timolol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-017-0534-z


  3 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28719370
[Au] Autor:Choo W
[Ad] Endereço:National Skin Centre Pte. Ltd., Singapore. winniechoo@nsc.com.sg.
[Ti] Título:Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas.
[So] Source:Int J Pharm Compd;21(4):282-289, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The discovery of beta-adrenergic blocker effects on infantile hemangiomas has affected the choice of treatment in recent years. Oral propranolol is effective in treating infantile hemangiomas, but the risk of systemic side effects remains a concern. Data from literature review reported positive clinical outcomes with no major adverse effects observed in children using topical beta-blocker such as timolol maleate. Topical application of timolol eye drop has been mentioned in few studies, most of which reported that the solution cannot stay on the site of application due to its fluidity. Adding hydroxyethyl cellulose into a timolol solution increased its viscosity by forming a hydrogel and thus changed the rheology property. The compounded timolol gel exhibited thixotropy property allowing better and longer contact at sites of application. Experimental data from literature review showed desirable characteristics and measurable flux of timolol across human stratum corneum. Gel dosage form allows easy and precise application and maximizes timolol's therapeutic efficacy at the sites of application.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Hemangioma/tratamento farmacológico
Soluções Oftálmicas/administração & dosagem
Timolol/administração & dosagem
[Mh] Termos MeSH secundário: Administração Tópica
Celulose/administração & dosagem
Celulose/análogos & derivados
Géis
Hemangioma/patologia
Seres Humanos
Lactente
Timolol/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Gels); 0 (Ophthalmic Solutions); 817W3C6175 (Timolol); 9004-34-6 (Cellulose); 9004-62-0 (hydroxyethylcellulose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  4 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28671925
[Au] Autor:Nanda T; Rasool N; Callahan AB; Stamper RL; Odel JG
[Ad] Endereço:*Columbia University College of Physicians and Surgeons †Harkness Eye Institute, Columbia University Medical Center, New York, NY ‡Department of Ophthalmology, University of California at San Francisco, San Francisco, CA.
[Ti] Título:Ophthalmic Timolol Hallucinations: A Case Series and Review of the Literature.
[So] Source:J Glaucoma;26(9):e214-e216, 2017 Sep.
[Is] ISSN:1536-481X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Systemic absorption and central nervous system (CNS) penetration of timolol drops are a well-studied phenomenon, resulting in common side effects such as bradycardia, bronchospasm, fatigue, and confusion. More serious CNS side effects, such as psychosis and depression, however, are rarely attributed to eye drops. We report a case series in which patients developed visual hallucinations secondary to topical ocular timolol use. METHODS: This study is a case series and review of the literature. RESULTS: Four patients with glaucoma developed visual hallucinations while using topical timolol. The patients were all elderly, caucasian females with associated CNS pathology. All patients had resolution of symptoms upon discontinuation and a positive retrial test to confirm the association. CONCLUSIONS: The rarity of this side effect and its anecdotal predilection for elderly, caucasian females with underlying neurological dysfunction, may involve a yet unknown predisposition or hypersensitivity to beta blocker action, such as blood brain barrier disruption leading to increased susceptibility to the medication. This case series highlights an important, although rare, side effect of this medication which clinicians should be aware of especially when using it in elderly patients who may have coexisting CNS pathology. It is important that this side effect be recognized and appropriately managed to prevent otherwise unnecessary investigations and treatment.
[Mh] Termos MeSH primário: Glaucoma/tratamento farmacológico
Alucinações/induzido quimicamente
Pressão Intraocular
Timolol/efeitos adversos
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Idoso de 80 Anos ou mais
Anti-Hipertensivos/efeitos adversos
Anti-Hipertensivos/uso terapêutico
Feminino
Seres Humanos
Soluções Oftálmicas/efeitos adversos
Timolol/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Ophthalmic Solutions); 817W3C6175 (Timolol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1097/IJG.0000000000000712


  5 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445315
[Au] Autor:Qi H; Gao C; Li Y; Feng X; Wang M; Zhang Y; Chen Y
[Ad] Endereço:aDepartment of Ophthalmology, Peking University Third Hospital bKey Laboratory of Vision Loss and Restoration, Ministry of Education cMoslem Hospital, Beijing, China.
[Ti] Título:The effect of Timolol 0.5% on the correction of myopic regression after LASIK.
[So] Source:Medicine (Baltimore);96(17):e6782, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUD: Postlaser in situ keratomileusis (post-LASIK) refractive regression is defined as the gradual, partial, or total loss of initial correction that limits the predictability, efficiency, and long-term stability of LASIK. Our study assesses the effect of Timolol 0.5% on the correction of myopic regression after LASIK. METHODS: This prospective, randomized, controlled study included 62 eyes of 62 patients with myopic regression of -1.18 ±â€Š0.86 diopters (D) after myopic LASIK. They were randomly assigned into either Group 1 who received Timolol 0.5% eye drops for 3 months or Group 2 who received artificial tears as control (during treatment). Patients were followed an additional 2 months after cessation of eye drops treatment (posttreatment). RESULTS: During treatment in Group 1, as the mean true intraocular pressure (IOPT) lowered significantly, regression stopped. As the mean IOPT increased significantly posttreatment and returned to its pretreatment level, regression recurred. The effective rate of Timolol therapy dropped from 62.5% during treatment to 40.6% posttreatment. On the contrary in Group 2, although the mean IOPT did not change significantly, regression continually happened as time passed. During treatment, the mean IOPT, uncorrected visual acuity, spherical equivalent (SE), and corneal refractive power showed significant difference between the 2 groups. In Group 1, the differences of effective rate of Timolol therapy between each of the 2 subgroups of age, gender, preoperative SE (PSE), or pretreatment time (how long we start treatment with Timolol post-LASIK) were not statistically significant. CONCLUSION: IOP-lowering eye drop Timolol was effective for the correction of myopic regression when a 0.5-D or greater myopic shift is detected after LASIK in patients regardless of age, gender, PSE, or anytime we started the treatment only if regression happened. However, the myopic regression recurred after cessation of Timolol treatment.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Ceratomileuse Assistida por Excimer Laser In Situ/efeitos adversos
Miopia/tratamento farmacológico
Miopia/cirurgia
Timolol/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Pressão Intraocular/efeitos dos fármacos
Masculino
Miopia/fisiopatologia
Soluções Oftálmicas
Falha de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Ophthalmic Solutions); 817W3C6175 (Timolol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006782


  6 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28411778
[Au] Autor:Jeon H; Cohen B
[Ad] Endereço:Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: hjeon5@jhmi.edu.
[Ti] Título:Lack of efficacy of topical timolol for cutaneous telangiectasias in patients with hereditary hemorrhagic telangiectasia: Results of a pilot study.
[So] Source:J Am Acad Dermatol;76(5):997-999, 2017 05.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Dermatopatias/tratamento farmacológico
Telangiectasia Hemorrágica Hereditária/tratamento farmacológico
Telangiectasia/tratamento farmacológico
Timolol/administração & dosagem
[Mh] Termos MeSH secundário: Administração Tópica
Seres Humanos
Projetos Piloto
Estudos Prospectivos
Falha de Tratamento
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 817W3C6175 (Timolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170417
[St] Status:MEDLINE


  7 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28301661
[Au] Autor:Oke I; Alkharashi M; Petersen RA; Ashenberg A; Shah AS
[Ad] Endereço:Harvard Medical School, Boston, Massachusetts2Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts3Department of Internal Medicine, Carney Hospital, Boston, Massachusetts.
[Ti] Título:Treatment of Ocular Pyogenic Granuloma With Topical Timolol.
[So] Source:JAMA Ophthalmol;135(4):383-385, 2017 Apr 01.
[Is] ISSN:2168-6173
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Pyogenic granulomas, acquired vascular lesions, form on the ocular or palpebral surface related to inflammation from chalazia, trauma, or surgery. They can be unsightly, spontaneously bleed, and cause irritation to patients. Observations: A case series is presented of 4 consecutive children with acquired ocular surface pyogenic granulomas treated at Boston Children's Hospital from 2014 to 2016 with only topical timolol, 0.5%, twice daily for a minimum of 21 days. In all cases, complete resolution occurred within the treatment period with no recurrence for at least 3 months. There were no adverse effects from the timolol during follow-up. Conclusions and Relevance: This case series of 4 children, while limited to no greater than 12 weeks of follow-up and without control children, suggests that ocular surface pyogenic granulomas respond to topical timolol treatment, which has a lower adverse-effect profile than conventional topical steroid treatments or other medical or surgical therapies. If confirmed in larger studies with longer follow-up and controls, this may be the desired treatment modality.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/uso terapêutico
Doenças da Túnica Conjuntiva/tratamento farmacológico
Granuloma Piogênico/tratamento farmacológico
Timolol/uso terapêutico
[Mh] Termos MeSH secundário: Administração Tópica
Criança
Pré-Escolar
Doenças da Túnica Conjuntiva/diagnóstico
Doenças da Túnica Conjuntiva/etiologia
Feminino
Granuloma Piogênico/diagnóstico
Granuloma Piogênico/etiologia
Seres Humanos
Masculino
Estudos Retrospectivos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 817W3C6175 (Timolol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.1001/jamaophthalmol.2017.0110


  8 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28199397
[Au] Autor:Lorenz K; Wasielica-Poslednik J; Bell K; Renieri G; Keicher A; Ruckes C; Pfeiffer N; Thieme H
[Ad] Endereço:Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
[Ti] Título:Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma.
[So] Source:PLoS One;12(2):e0171636, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. MATERIALS AND METHODS: Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hypertension rate and change of conjunctival redness 3 and 6 months post-op. Safety was assessed based on the documentation of adverse events. RESULTS: Preoperative treatment with topical dorzolamide/timolol was non-inferior to oral acetazolamide and topical dexamethasone in terms of IOP reduction 3 months after trabeculectomy (adjusted means -8.12 mmHg versus -8.30 mmHg; Difference: 0.18; 95% CI -1.91 to 2.26, p = 0.8662). Similar results were found 6 months after trabeculectomy (-9.13 mmHg versus -9.06 mmHg; p = 0.9401). Comparable results were also shown for both groups concerning the classification of the filtering bleb, corneal staining, and numbers of treatments with 5-FU, needlings and suture lyses. More patients reported AEs in the acetazolamide/dexamethasone group than in the dorzolamide/timolol group. DISCUSSION: Preoperative, preservative-free, fixed-dose dorzolamide/timolol seems to be equally effective as preoperative acetazolamide and dexamethasone and has a favourable safety profile.
[Mh] Termos MeSH primário: Acetazolamida/administração & dosagem
Dexametasona/administração & dosagem
Glaucoma/tratamento farmacológico
Soluções Oftálmicas/administração & dosagem
Sulfonamidas/administração & dosagem
Tiofenos/administração & dosagem
Timolol/administração & dosagem
[Mh] Termos MeSH secundário: Acetazolamida/farmacologia
Idoso
Anti-Hipertensivos/uso terapêutico
Dexametasona/farmacologia
Combinação de Medicamentos
Feminino
Fluoruracila/uso terapêutico
Glaucoma/patologia
Glaucoma/cirurgia
Seres Humanos
Pressão Intraocular/efeitos dos fármacos
Masculino
Meia-Idade
Hipertensão Ocular/tratamento farmacológico
Soluções Oftálmicas/farmacologia
Cuidados Pré-Operatórios
Estudos Prospectivos
Sulfonamidas/farmacologia
Tiofenos/farmacologia
Timolol/farmacologia
Trabeculectomia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drug Combinations); 0 (Ophthalmic Solutions); 0 (Sulfonamides); 0 (Thiophenes); 0 (dorzolamide-timolol combination); 7S5I7G3JQL (Dexamethasone); 817W3C6175 (Timolol); O3FX965V0I (Acetazolamide); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171636


  9 / 3469 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28176172
[Au] Autor:Karaskiewicz J; Penkala K; Mularczyk M; Lubinski W
[Ad] Endereço:Department of Ophthalmology, Pomeranian Medical University, Powstanców Wielkopolskich 72 Str., Szczecin, Poland.
[Ti] Título:Evaluation of retinal ganglion cell function after intraocular pressure reduction measured by pattern electroretinogram in patients with primary open-angle glaucoma.
[So] Source:Doc Ophthalmol;134(2):89-97, 2017 Apr.
[Is] ISSN:1573-2622
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To evaluate retinal ganglion cell (RGC) function after intraocular pressure (IOP) reduction measured by pattern electroretinogram (PERG) in patients with newly diagnosed, non-treated preperimetric and early stages of primary open-angle glaucoma (POAG). METHODS: Twenty-four eyes from 24 patients with POAG: 11 eyes with preperimetric glaucoma and 13 eyes with early glaucoma received Ganfort (bimatoprost + timolol) once a day for a period of 1 month. Before and after the treatment, following measurements were analyzed: IOP, mean ocular perfusion pressure (MOPP), peak time of P50 and amplitude of P50 and N95 waves in PERG (ISCEV standard 2012). Correlations between PERG P50 and N95 waves, IOP and MOPP were calculated. RESULTS: After therapy, IOP significantly decreased in all eyes, on average 31%. Significant increase in MOPP in all eyes on average 14% was detected. PERG amplitude of P50 and N95 waves increased in 75 and 79% eyes, respectively, on average P50 by 28% and N95 by 38%. There were no significant interactions between the change of PERG parameters in time and stage of glaucoma. CONCLUSIONS: Significant IOP-lowering therapy can improve RGC function measured by PERG, in patients with preperimetric and early stages of POAG.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Bimatoprost/uso terapêutico
Glaucoma de Ângulo Aberto/tratamento farmacológico
Glaucoma de Ângulo Aberto/fisiopatologia
Pressão Intraocular/fisiologia
Células Ganglionares da Retina/fisiologia
Timolol/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Análise de Variância
Eletrorretinografia/métodos
Feminino
Seres Humanos
Masculino
Meia-Idade
Visão Ocular
Testes de Campo Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 817W3C6175 (Timolol); QXS94885MZ (Bimatoprost)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170209
[St] Status:MEDLINE
[do] DOI:10.1007/s10633-017-9575-0


  10 / 3469 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28165835
[Au] Autor:Selen F; Tekeli O; Yanik Ö
[Ad] Endereço:Department of Ophthalmology, Faculty of Medicine, Ankara University , Ankara, Turkey .
[Ti] Título:Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs.
[So] Source:J Ocul Pharmacol Ther;33(3):170-175, 2017 Apr.
[Is] ISSN:1557-7732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy. METHODS: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month). RESULTS: Statistically significant increases were detected in the flare values in the bimatoprost and latanoprost groups (P < 0.001, P = 0.011, respectively). Significant increases were also found in CMT values measured in these 2 groups (P < 0.001, P = 0.002, respectively). However, increased flare and CMT values were not clinically manifested as uveitis and macular edema. Flare and CMT values did not change statistically in the timolol maleate and control groups. CONCLUSIONS: Although the use of prostaglandin (PG) analogs was found to be associated with increased flare and CMT, these increases were not clinically significant. PG analog monotherapy may be safely and effectively used in the treatment of glaucoma.
[Mh] Termos MeSH primário: Câmara Anterior/efeitos dos fármacos
Anti-Hipertensivos/farmacologia
Bimatoprost/farmacologia
Degeneração Macular/tratamento farmacológico
Prostaglandinas F Sintéticas/farmacologia
Timolol/farmacologia
[Mh] Termos MeSH secundário: Administração Tópica
Câmara Anterior/patologia
Anti-Hipertensivos/administração & dosagem
Bimatoprost/administração & dosagem
Feminino
Glaucoma/diagnóstico
Glaucoma/tratamento farmacológico
Seres Humanos
Degeneração Macular/metabolismo
Degeneração Macular/patologia
Masculino
Meia-Idade
Prostaglandinas F Sintéticas/administração & dosagem
Timolol/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Prostaglandins F, Synthetic); 6Z5B6HVF6O (latanoprost); 817W3C6175 (Timolol); QXS94885MZ (Bimatoprost)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1089/jop.2016.0128



página 1 de 347 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde